Lucid Diagnostics Inc (LUCD) FinancialsLUCDLucid Diagnostics Inc

Evaluating the bottom line, Lucid Diagnostics Inc maintains a gross margin of -5.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -868.45%, while the net margin is -792.88%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LUCD converts its operational activities into shareholder value.

In the context of the broader market, LUCD competes directly with industry leaders such as NRXS and KEQU. With a market capitalization of $78.48M, it holds a significant position in the sector. When comparing efficiency, LUCD's gross margin of -5.16% stands against NRXS's 85.87% and KEQU's 29.61%. Such benchmarking helps identify whether Lucid Diagnostics Inc is trading at a premium or discount relative to its financial performance.

Lucid Diagnostics has shown fluctuating revenues, with Q2 2026 revenue at $1,474,000, but net income remains negative, with a loss of $14,715,000. The gross margin has improved to -20.15% in Q2 2026, indicating some operational improvements.